Cisen Pharmaceutical Co., Ltd. (603367.SS)
CNY 13.42
(-0.37%)
CNY 13.42
(-0.37%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -812.71 Million CNY | 3.17% |
| 2022 | -839.34 Million CNY | -5.53% |
| 2021 | -795.34 Million CNY | -139.98% |
| 2020 | -331.41 Million CNY | -17.35% |
| 2019 | -282.41 Million CNY | -30.44% |
| 2018 | -216.51 Million CNY | 82.67% |
| 2017 | -1.24 Billion CNY | -594.49% |
| 2016 | -179.9 Million CNY | -205.91% |
| 2015 | -58.8 Million CNY | -144.76% |
| 2014 | 131.39 Million CNY | 59.65% |
| 2013 | 82.3 Million CNY | 205.63% |
| 2012 | -77.91 Million CNY | 45.63% |
| 2011 | -143.3 Million CNY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -365.52 Million CNY | 50.2% |
| 2024 Q3 | -532.77 Million CNY | -45.76% |
| 2024 Q1 | -734.01 Million CNY | 9.68% |
| 2023 Q1 | -761.53 Million CNY | 9.27% |
| 2023 FY | -812.71 Million CNY | 3.17% |
| 2023 Q2 | -628.89 Million CNY | 17.42% |
| 2023 Q3 | -774.97 Million CNY | -23.23% |
| 2023 Q4 | -812.71 Million CNY | -4.87% |
| 2022 Q2 | -481.75 Million CNY | 26.02% |
| 2022 Q4 | -839.34 Million CNY | -48.47% |
| 2022 FY | -839.34 Million CNY | -5.53% |
| 2022 Q1 | -651.22 Million CNY | 18.12% |
| 2022 Q3 | -565.34 Million CNY | -17.35% |
| 2021 Q4 | -795.34 Million CNY | -133.85% |
| 2021 FY | -795.34 Million CNY | -139.98% |
| 2021 Q1 | -280.22 Million CNY | 15.45% |
| 2021 Q3 | -340.11 Million CNY | -49.1% |
| 2021 Q2 | -228.11 Million CNY | 18.6% |
| 2020 Q2 | -154.18 Million CNY | 6.64% |
| 2020 FY | -331.41 Million CNY | -17.35% |
| 2020 Q1 | -165.15 Million CNY | 41.52% |
| 2020 Q3 | -491.03 Million CNY | -218.48% |
| 2020 Q4 | -331.41 Million CNY | 32.51% |
| 2019 Q3 | -573.02 Million CNY | -86.32% |
| 2019 FY | -282.41 Million CNY | -30.44% |
| 2019 Q4 | -282.41 Million CNY | 50.71% |
| 2019 Q2 | -307.55 Million CNY | 12.93% |
| 2019 Q1 | -353.23 Million CNY | -2.16% |
| 2018 FY | -216.51 Million CNY | 82.67% |
| 2018 Q4 | -345.76 Million CNY | -20.18% |
| 2018 Q1 | -406.76 Million CNY | 71.02% |
| 2018 Q2 | -602.87 Million CNY | -48.21% |
| 2018 Q3 | -287.71 Million CNY | 52.28% |
| 2017 Q3 | -1.09 Billion CNY | -1740.28% |
| 2017 Q1 | 549.9 Million CNY | 405.67% |
| 2017 Q4 | -1.4 Billion CNY | -28.47% |
| 2017 FY | -1.24 Billion CNY | -594.49% |
| 2017 Q2 | -59.35 Million CNY | -110.79% |
| 2016 FY | -179.9 Million CNY | -205.91% |
| 2016 Q4 | -179.9 Million CNY | 0.0% |
| 2015 Q4 | -58.8 Million CNY | 0.0% |
| 2015 FY | -58.8 Million CNY | -144.76% |
| 2015 Q1 | 65.29 Million CNY | 0.0% |
| 2015 Q2 | 65.29 Million CNY | 0.0% |
| 2014 FY | 131.39 Million CNY | 59.65% |
| 2013 FY | 82.3 Million CNY | 205.63% |
| 2012 FY | -77.91 Million CNY | 45.63% |
| 2011 FY | -143.3 Million CNY | 0.0% |